Literature DB >> 17043464

The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia.

Robert S Katz1, Amy R Heard, Megan Mills, Frank Leavitt.   

Abstract

Cognitive dysfunction in patients with rheumatic disease encompasses a range of impairment. Their prevalence, co-occurrence, and impact on symptom severity were assessed in 57 patients with fibromyalgia (FMS) and 57 patients with rheumatic disease without FMS. Information pertaining to memory decline, mental confusion, and speech difficulty was extracted from questions embedded in a health questionnaire and a blind retrospective chart review. Pain, morning stiffness, fatigue, and sleep difficulty were established on a 0- to 100-mm visual analog scale. Variables of mental confusion, fatigue, tension, depression, anger, and vigor were assessed using the Profile of Mood States.Compared with the non-FMS sample, patients with FMS complained more often of memory decline (70.2-24.6%), mental confusion (56.1-12.3%), and speech difficulty (40.4-3.5%). Memory decline and mental confusion were coupled more often in patients with FMS (50.9-8.8%). Patients with FMS with this combination of cognitive problems reported more pain (76.0-45.4%), stiffness (79.7-43.7%), fatigue (79.6-52.6%), and disturbed sleep (59.2-36.6%) compared with patients with FMS with memory problems alone. Patients with rheumatic disease substantially differ in cognitive vulnerability, with patients with FMS at considerably higher risk for cognitive difficulty. More importantly, the prevalence of a combined disturbance in memory and mental clarity is high and closely associated with the perception of increased illness severity and diminished mental health in FMS. That this linkage has the possibility of having a great deal to do with an important clinical variant of FMS underscores the need for greater clinical recognition of this underrecognized pattern and for further research.Patients with fibromyalgia frequently report memory and concentration problems, especially if asked about them. Clinicians could judge these complaints as similar to adult attention deficit syndrome and reassure the patient. Trying medication to improve attention and concentration is sensible but untested in fibromyalgia.

Entities:  

Year:  2004        PMID: 17043464     DOI: 10.1097/01.rhu.0000120895.20623.9f

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  45 in total

Review 1.  [Cognitive impairment in patients suffering from fibromyalgia. An underestimated problem].

Authors:  T Schmidt-Wilcke; P Wood; R Lürding
Journal:  Schmerz       Date:  2010-02       Impact factor: 1.107

2.  Understanding fibromyalgia and its related disorders.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  Fibrofog and fibromyalgia: a narrative review and implications for clinical practice.

Authors:  Howard M Kravitz; Robert S Katz
Journal:  Rheumatol Int       Date:  2015-01-13       Impact factor: 2.631

4.  Development and initial validation of a brief self-report measure of cognitive dysfunction in fibromyalgia.

Authors:  Anna L Kratz; Stephen G Schilling; Jenna Goesling; David A Williams
Journal:  J Pain       Date:  2015-03-04       Impact factor: 5.820

5.  Fibrofog in Daily Life: An Examination of Ambulatory Subjective and Objective Cognitive Function in Fibromyalgia.

Authors:  Anna L Kratz; Daniel Whibley; Samsuk Kim; Martin Sliwinski; Daniel Clauw; David A Williams
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11-09       Impact factor: 4.794

6.  Cognitive performance in women aged 50 years and older with and without fibromyalgia.

Authors:  Barbara J Cherry; Laura Zettel-Watson; Renee Shimizu; Ian Roberson; Dana N Rutledge; Caroline J Jones
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2012-12-28       Impact factor: 4.077

7.  Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.

Authors:  Robert H Palmer; Antonia Periclou; Pradeep Banerjee
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

8.  Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination.

Authors:  Jose Rodríguez-Andreu; Rosario Ibáñez-Bosch; Amparo Portero-Vázquez; Xavier Masramon; Javier Rejas; Rafael Gálvez
Journal:  BMC Musculoskelet Disord       Date:  2009-12-21       Impact factor: 2.362

9.  Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis.

Authors:  Robert M Bennett; Jon Russell; Joseph C Cappelleri; Andrew G Bushmakin; Gergana Zlateva; Alesia Sadosky
Journal:  BMC Musculoskelet Disord       Date:  2010-06-28       Impact factor: 2.362

10.  Automated neuropsychiatric measurements of information processing in fibromyalgia.

Authors:  Brian Walitt; Tresa Roebuck-Spencer; Joseph Bleiberg; Gregory Foster; Arthur Weinstein
Journal:  Rheumatol Int       Date:  2007-11-23       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.